STRATA Announces JCAD Publication: Photopneumatic Technology for the Treatment of Mild-to-Moderate Acne Vulgaris
July 11 2023 - 8:00AM
STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology
company dedicated to developing, commercializing and marketing
innovative products for the treatment of dermatologic conditions,
today announced the Journal of Clinical and Aesthetic Dermatology
(JCAD) published a review and an expert perspectives article in the
June 2023 Supplemental edition titled, “Photopneumatic Technology
for the Treatment of Mild-to-Moderate Acne Vulgaris.”
In the review, Gilly Munavalli, MD, highlighted the TheraClear®X
system, which included its mechanism of action, key features of the
device, and the clinical outcomes experienced. Dr. Munavalli also
recounted anecdotal results of using the device in the treatment of
acne.
“TheraClearX is a tool we often utilize in the clinic to treat
mild-to-moderate acne,” stated Dr. Gilly Munavalli, Medical
Director and Founder of Dermatology, Laser, & Vein Specialists
of the Carolinas in Charlotte, North Carolina. “With patients
experiencing little-to-no downtime and visible reductions in
redness early on in their treatment, we believe the TheraClearX
system is an effective, non-pharmaceutical acne treatment.”
The clinical perspective article expands on the expert
perspectives derived from a virtual roundtable conducted in
February 2023 which featured Ashish Bhatia, MD, FAAD, Cheryl M.
Burgess, MD, FAAD, Gilly S. Munavalli, MD, MHS, FACMS, and Jason L.
Smith, MD. The roundtable participants discussed the TheraClearX
system, its mechanism of action, the customizable device settings,
treatment protocols, and practice integration. Key takeaways from
the expert perspectives article include:
- It is safe and efficacious, with visible improvement of acne as
soon as the second treatment.
- Additional benefits include visible improvement of pore size,
erythema, and skin texture.
- Settings can be customized to treat all Fitzpatrick skin
types.
- Treatment sessions are quick and comfortable, with no downtime
resulting in compliant and satisfied patients.
- Ideal for a new acne patient wanting to expedite their acne
clearance and/or an existing patient wanting to enhance their
current acne regimen.
“The TheraClearX review and expert perspectives
article highlights the device’s safety and efficacy and emphasizes
the visible improvement patients often experience soon after
beginning treatment,” stated Bob Moccia, Chief Executive Officer of
STRATA Skin Sciences. “Importantly, the information presented in
the JCAD supplement expands on how the TheraClearX device fits into
the acne treatment landscape and how the device can be seamlessly
integrated into a physician’s practice.”
About STRATA Skin Sciences, Inc.STRATA Skin
Sciences is a medical technology company dedicated to developing,
commercializing and marketing innovative products for the in-office
treatment of various dermatologic conditions such as psoriasis,
vitiligo, and acne. Its products include the XTRAC® excimer laser,
VTRAC® lamp systems, and the TheraClear®X Acne Therapy System.
STRATA is proud to offer these exciting
technologies in the U.S. through its unique Partnership Program.
STRATA’s popular partnership approach includes a fee per treatment
cost structure versus an equipment purchase, installation and use
of the device, on-site training for practice personnel, service and
maintenance of the equipment, dedicated account and customer
service associates, and co-op advertising support to help raise
awareness and promote the program within the practice.
Safe HarborThis press release
includes "forward-looking statements" within the meaning of the
Securities Litigation Reform Act of 1995. These statements include
but are not limited to the Company’s plans, objectives,
expectations and intentions and may contain words such as “will,”
“may,” “seeks,” and “expects,” that suggest future events or
trends. These statements, the Company’s ability to launch and sell
an acne treatment device and to integrate that device into its
product offerings, the Company’s ability to develop, launch and
sell products recently acquired or to be developed in the future,
the Company’s ability to develop social media marketing campaigns,
direct to dermatologist marketing campaigns, and the Company’s
ability to build a leading franchise in dermatology and aesthetics,
are based on the Company’s current expectations and are inherently
subject to significant uncertainties and changes in circumstances.
Actual results may differ materially from the Company’s
expectations due to financial, economic, business, competitive,
market, regulatory, adverse market conditions labor supply
shortages, or supply chain interruptions resulting from the
coronavirus, fiscal, and political factors, responses, or
conditions affecting the Company, the medical device industry and
our customers and patients in general, as well as more specific
risks and uncertainties set forth in the Company’s SEC reports on
Forms 10-Q and 10-K. Given such uncertainties, any or all these
forward-looking statements may prove to be incorrect or unreliable.
The statements in this press release are made as of the date of
this press release, even if subsequently made available by the
Company on its website or otherwise. The Company does not undertake
any obligation to update or revise these statements to reflect
events or circumstances occurring after the date of this press
release. The Company urges investors to carefully review its SEC
disclosures available at www.sec.gov and
www.strataskinsciences.com.
Investor Contact:Rich CockrellCG CapitalPhone:
+1 (404) 736-3838sskn@cg.capital
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From Apr 2024 to May 2024
Strata Skin Sciences (NASDAQ:SSKN)
Historical Stock Chart
From May 2023 to May 2024